NO132906B - - Google Patents
Download PDFInfo
- Publication number
- NO132906B NO132906B NO3538/71A NO353871A NO132906B NO 132906 B NO132906 B NO 132906B NO 3538/71 A NO3538/71 A NO 3538/71A NO 353871 A NO353871 A NO 353871A NO 132906 B NO132906 B NO 132906B
- Authority
- NO
- Norway
- Prior art keywords
- compound
- compounds
- acid
- hydroxy
- chlorophenoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 15
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 3
- 229960001214 clofibrate Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- JNGNWSCREXDRBJ-UHFFFAOYSA-N 1,3-dimethyl-7-(oxiran-2-ylmethyl)purine-2,6-dione Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CC1CO1 JNGNWSCREXDRBJ-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 230000002402 anti-lipaemic effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- -1 chlorphenoxy Chemical group 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- FPDNKWSQWXOPSC-UHFFFAOYSA-N 1-(methylamino)ethanol Chemical compound CNC(C)O FPDNKWSQWXOPSC-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- FKKPRBRKFRANQC-UHFFFAOYSA-N 3,7-dihydropurine-2,6-dione;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.O=C1NC(=O)NC2=C1NC=N2 FKKPRBRKFRANQC-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- GEPMAHVDJHFBJI-UHFFFAOYSA-N 7-[2-hydroxy-3-[2-hydroxyethyl(methyl)amino]propyl]-1,3-dimethylpurine-2,6-dione;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2CC(O)CN(CCO)C GEPMAHVDJHFBJI-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000295146 Gallionellaceae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000011421 subcutaneous treatment Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUCI1033A HU165315B (ja) | 1970-09-25 | 1970-09-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO132906B true NO132906B (ja) | 1975-10-20 |
| NO132906C NO132906C (ja) | 1976-01-28 |
Family
ID=10994392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO3538/71A NO132906C (ja) | 1970-09-25 | 1971-09-24 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US3801578A (ja) |
| JP (1) | JPS5111167B1 (ja) |
| AT (1) | AT315197B (ja) |
| AU (1) | AU457853B2 (ja) |
| BE (1) | BE773084A (ja) |
| CH (1) | CH557832A (ja) |
| CS (1) | CS169921B1 (ja) |
| DD (1) | DD101896A1 (ja) |
| DK (1) | DK129525B (ja) |
| ES (1) | ES395402A1 (ja) |
| FI (1) | FI54483C (ja) |
| FR (1) | FR2107964B1 (ja) |
| GB (1) | GB1341612A (ja) |
| HU (1) | HU165315B (ja) |
| IL (1) | IL37623A (ja) |
| NL (1) | NL175825C (ja) |
| NO (1) | NO132906C (ja) |
| SE (1) | SE385708B (ja) |
| SU (1) | SU447889A3 (ja) |
| YU (1) | YU237571A (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4092417A (en) * | 1976-12-08 | 1978-05-30 | Johann A. Wulfing | Theophylline salts of 5-methylisoxazole-3-carboxylic acid |
| US4263301A (en) * | 1980-01-24 | 1981-04-21 | Shell Oil Company | β-Phenyl-β-hydroxyethylaminoalkyltheophyllines as inhibitors of biosynthesis of triglycerides |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1089763B (de) * | 1957-10-26 | 1960-09-29 | Wuelfing J A Fa | Verfahren zur Herstellung des 7-[ª‰-Oxy-ª†-(methyl-ª‰-oxyaethylamino)-propyl]-theophyllin-nikotinats |
-
1970
- 1970-09-25 HU HUCI1033A patent/HU165315B/hu unknown
-
1971
- 1971-08-31 IL IL37623A patent/IL37623A/xx unknown
- 1971-09-02 US US00177424A patent/US3801578A/en not_active Expired - Lifetime
- 1971-09-02 CH CH1288371A patent/CH557832A/xx not_active IP Right Cessation
- 1971-09-03 AU AU33093/71A patent/AU457853B2/en not_active Expired
- 1971-09-03 GB GB4127171A patent/GB1341612A/en not_active Expired
- 1971-09-09 AT AT782871A patent/AT315197B/de not_active IP Right Cessation
- 1971-09-10 CS CS6504A patent/CS169921B1/cs unknown
- 1971-09-16 FR FR7133341A patent/FR2107964B1/fr not_active Expired
- 1971-09-17 DK DK456571AA patent/DK129525B/da not_active IP Right Cessation
- 1971-09-20 YU YU02375/71A patent/YU237571A/xx unknown
- 1971-09-22 SE SE7111994A patent/SE385708B/xx unknown
- 1971-09-22 NL NLAANVRAGE7113000,A patent/NL175825C/xx not_active IP Right Cessation
- 1971-09-22 FI FI2647/71A patent/FI54483C/fi active
- 1971-09-22 SU SU1700601A patent/SU447889A3/ru active
- 1971-09-22 JP JP46074187A patent/JPS5111167B1/ja active Pending
- 1971-09-23 DD DD157920A patent/DD101896A1/xx unknown
- 1971-09-24 NO NO3538/71A patent/NO132906C/no unknown
- 1971-09-24 BE BE773084A patent/BE773084A/xx not_active IP Right Cessation
- 1971-09-24 ES ES395402A patent/ES395402A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AU457853B2 (en) | 1975-02-13 |
| SE385708B (sv) | 1976-07-19 |
| FR2107964B1 (ja) | 1975-02-07 |
| BE773084A (fr) | 1972-01-17 |
| US3801578A (en) | 1974-04-02 |
| NL175825C (nl) | 1985-01-02 |
| NL175825B (nl) | 1984-08-01 |
| GB1341612A (en) | 1973-12-25 |
| FI54483C (fi) | 1978-12-11 |
| DE2144225B2 (de) | 1976-07-22 |
| DE2144225A1 (de) | 1972-03-30 |
| NO132906C (ja) | 1976-01-28 |
| YU237571A (en) | 1982-02-28 |
| CH557832A (de) | 1975-01-15 |
| HU165315B (ja) | 1974-08-28 |
| IL37623A0 (en) | 1971-11-29 |
| CS169921B1 (ja) | 1976-08-27 |
| ES395402A1 (es) | 1975-11-01 |
| AT315197B (de) | 1974-05-10 |
| DK129525C (ja) | 1975-03-17 |
| SU447889A3 (ru) | 1974-10-25 |
| JPS5111167B1 (ja) | 1976-04-09 |
| NL7113000A (ja) | 1972-03-28 |
| DD101896A1 (ja) | 1973-11-20 |
| FR2107964A1 (ja) | 1972-05-12 |
| AU3309371A (en) | 1973-03-08 |
| IL37623A (en) | 1974-10-22 |
| DK129525B (da) | 1974-10-21 |
| FI54483B (fi) | 1978-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2186792B1 (en) | 2-(a-hydroxypentyl) benzoate and its preparation and use | |
| NO172343B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive askorbinsyrederivater | |
| US4169157A (en) | Therapeutic preparations for peptic ulcers comprising aliphatic ketone derivative | |
| EP3838887B1 (en) | 2-(1-acyloxypentyl) benzoic acid salt formed by basic amino acid or aminoguanidine, preparation method therefor and uses thereof | |
| WO1991016338A1 (en) | S-(lower fatty acid)-substituted glutathione derivative | |
| US4594443A (en) | Derivatives of 4-phenyl-4-oxo-buten-2-oic acid and therapeutic use thereof | |
| US4760078A (en) | Immunomodulator 1,2-dithiol-3-thione derivative composition, use method and process of producing the same | |
| IE52444B1 (en) | New derivatives of phenyl aliphatic carboxylic acids,their preparation,their use as medicaments and compositions containing them | |
| NO132906B (ja) | ||
| US4473583A (en) | Compositions containing certain derivatives of 4-phenyl-4-oxobuten-2-oic acid and methods of treatment using them | |
| CN116554127A (zh) | 哌嗪取代苯酚类衍生物及其用途 | |
| JP7498504B2 (ja) | 脳神経または心臓保護剤としてのアミノチオール系化合物の使用 | |
| EP0172058A1 (fr) | Nouvelles phényl-naphthyridines, leur procédé de préparation, médicaments les contenant, notamment anti-ulcères | |
| CN113214097B (zh) | 治疗阿尔茨海默病的化合物 | |
| GB2193210A (en) | Glycine derivatives | |
| HU181944B (en) | Process for preparing /+/-/3alpha,16alpha/-14-imino-/15h/-eburnamenine | |
| CH449652A (fr) | Procédé de préparation de nouvelles hydroxydiamines | |
| CZ277725B6 (en) | Method of separating (+)-2-(6-methoxy-2-naphthyl)propionic acid from a mixture of (+) and (-)-2-(6-methoxy-2-naphthyl)propionic acids | |
| JPS588379B2 (ja) | パラ−イソプチルヒドロアトロバ酸誘導体およびその製法 | |
| CN101903352A (zh) | 取代的3-羟基吡啶系化合物及其药物组合物 | |
| US4436752A (en) | Treatment of gastric and gastro-duodenal disorders with derivatives of phenyl aliphatic carboxylic acids | |
| FR2631963A1 (fr) | Derives imidazoliques, leur preparation et leur application a titre de medicament | |
| CS208752B2 (en) | Method of making the r-n-(2-fenyl-2-hydroxyethyl)-3-fenyl propylamines | |
| JPS6354338A (ja) | ４−フエニル−４−オキソ−２−ブテン酸の新誘導体、その製造法、薬剤としての使用及びそれを含有する組成物 | |
| KR830002843B1 (ko) | 알킬-케토헥소 피라노사이드 유도체의 제조방법 |